Ageless Pep Academy Clinical Education · Licensed Prescribers

PMID-21300339 – Leuprolide vs Oral Contraceptives for Endometriosis Pain

PMID-21300339 – Leuprolide vs Oral Contraceptives for Endometriosis Pain

Guzick DS, Huang LS, Broadman BA, Nealon M, Hornstein MD. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril. 2011;95(5):1568-73.

Quick Reference

Property Value
PMID 21300339
DOI 10.1016/j.fertnstert.2011.01.027
Year 2011
Journal Fertility and Sterility
Study Type RCT
Evidence Level II
Sample 47 women with endometriosis
Peptide(s) Studied Leuprolide

Key Findings

  • Both leuprolide depot and continuous oral contraceptives produced statistically significant reductions in pelvic pain scores from baseline
  • No significant differences between groups in the extent of pain reduction across multiple validated pain instruments (Biberoglu & Behrman scale, Numeric Rating Scale, Beck Depression Inventory)
  • Both treatments achieved clinically meaningful improvements in endometriosis-associated pelvic pain
  • Continuous oral contraceptives may represent a less costly and better-tolerated alternative to leuprolide for pain management

Study Design

Randomized, open-label, parallel-group trial comparing leuprolide depot 11.25 mg IM every 3 months versus continuous combined oral contraceptives over 48 weeks. Pain was assessed using the Biberoglu & Behrman (B&B) pain scale, Numeric Rating Scale (NRS), and Beck Depression Inventory (BDI).

Limitations

  • Small sample size (n=47) limits power to detect moderate differences
  • Open-label design introduces potential for bias
  • Single-center study limits generalizability
  • Did not assess endometriotic lesion regression or fertility outcomes

Clinical Relevance

This trial is important because it demonstrated that continuous oral contraceptives — a more accessible and less expensive treatment — provided comparable pain relief to leuprolide depot for endometriosis. This finding supports a stepped approach starting with oral contraceptives before escalating to GnRH agonist therapy.

Related

#research #RCT #peptide #reproductive #evidence-level-II